Kalvista Book Value Per Share from 2010 to 2024

KALV Stock

USD 9.33 0.01 0.11%

Kalvista Pharmaceuticals Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share will likely drop to -37.75 in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Kalvista Pharmaceuticals according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

5.61577774

Current Value

(37.75)

Quarterly Volatility

21.28007308

Credit Downgrade

Yuan Drop

Covid

Check Kalvista Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kalvista Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 424 K, Interest Expense of 0.0 or Selling General Administrative of 4.9 M, as well as many indicators such as Price To Sales Ratio of 46.33, Dividend Yield of 0.0 or Days Sales Outstanding of 268. Kalvista financial statements analysis is a perfect complement when working with Kalvista Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Kalvista Pharmaceuticals Correlation against competitors.

For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.

Latest Kalvista Pharmaceuticals' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Kalvista Pharmaceuticals over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Kalvista Pharmaceuticals' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kalvista Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 4.01 X

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Kalvista Book Value Per Share Regression Statistics

	Arithmetic Mean	(6.54)
	Geometric Mean	8.99
	Coefficient Of Variation	(325.42)
	Mean Deviation	17.98
	Median	4.51
	Standard Deviation	21.28
	Sample Variance	452.84
	Range	59.9761
	R-Value	0.23
	Mean Square Error	461.55
	R-Squared	0.05
	Significance	0.41
	Slope	1.10
	Total Sum of Squares	6,340

Kalvista Book Value Per Share History

	2023	5.62
	2022	5.77
	2021	7.56
	2020	13.47
	2019	4.72
	2018	6.41
	2017	2.64

Other Fundumenentals of Kalvista Pharmaceuticals

Tangible Book Value Per Share

Kalvista Pharmaceuticals Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Long Term Debt Total	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.42	-0.62	-0.82	0.75	-0.21	1.0	-0.52	0.8	0.37	0.73	0.78	0.66	0.86	0.79	-0.09	0.19	0.94	0.94	0.7
Total Stockholder Equity	0.99		0.46	-0.62	-0.8	0.74	-0.34	0.99	-0.55	0.82	0.34	0.78	0.78	0.68	0.87	0.79	-0.12	0.15	0.94	0.94	0.68
Current Deferred Revenue	0.42	0.46		-0.79	-0.34	0.37	-0.38	0.43	-0.82	0.44	-0.59	0.12	0.27	0.51	0.48	0.51	0.47	-0.75	0.36	0.37	0.31
Net Debt	-0.62	-0.62	-0.79		0.43	-0.39	0.21	-0.62	0.8	-0.57	0.27	-0.3	-0.59	-0.72	-0.66	-0.59	-0.47	0.47	-0.51	-0.53	-0.38
Retained Earnings	-0.82	-0.8	-0.34	0.43		-0.96	0.06	-0.82	0.32	-0.84	-0.32	-0.6	-0.57	-0.49	-0.53	-0.7	0.11	-0.17	-0.76	-0.75	-0.9
Accounts Payable	0.75	0.74	0.37	-0.39	-0.96		-0.08	0.75	-0.35	0.83	0.24	0.58	0.39	0.43	0.4	0.63	-0.08	0.09	0.68	0.67	0.88
Total Liab	-0.21	-0.34	-0.38	0.21	0.06	-0.08		-0.21	0.35	-0.39	0.14	-0.54	-0.17	-0.27	-0.3	-0.26	0.25	0.21	-0.24	-0.23	-0.07
Total Current Assets	1.0	0.99	0.43	-0.62	-0.82	0.75	-0.21		-0.53	0.8	0.37	0.73	0.78	0.66	0.86	0.78	-0.08	0.18	0.94	0.94	0.69
Short Term Debt	-0.52	-0.55	-0.82	0.8	0.32	-0.35	0.35	-0.53		-0.55	0.2	-0.34	-0.45	-0.67	-0.56	-0.66	-0.3	0.45	-0.38	-0.4	-0.2
Common Stock	0.8	0.82	0.44	-0.57	-0.84	0.83	-0.39	0.8	-0.55		0.26	0.74	0.57	0.62	0.55	0.68	-0.11	0.05	0.77	0.77	0.83
Long Term Debt	0.37	0.34	-0.59	0.27	-0.32	0.24	0.14	0.37	0.2	0.26		0.59	0.43	0.23	0.28	0.34	-0.6	0.96	0.37	0.35	0.2
Long Term Debt Total	0.73	0.78	0.12	-0.3	-0.6	0.58	-0.54	0.73	-0.34	0.74	0.59		0.61	0.69	0.63	0.74	-0.31	0.45	0.66	0.66	0.45
Capital Surpluse	0.78	0.78	0.27	-0.59	-0.57	0.39	-0.17	0.78	-0.45	0.57	0.43	0.61		0.77	0.9	0.78	-0.14	0.27	0.74	0.74	0.43
Property Plant Equipment	0.66	0.68	0.51	-0.72	-0.49	0.43	-0.27	0.66	-0.67	0.62	0.23	0.69	0.77		0.77	0.88	0.2	0.05	0.58	0.59	0.36
Net Tangible Assets	0.86	0.87	0.48	-0.66	-0.53	0.4	-0.3	0.86	-0.56	0.55	0.28	0.63	0.9	0.77		0.79	-0.07	0.11	0.84	0.85	0.42
Net Receivables	0.79	0.79	0.51	-0.59	-0.7	0.63	-0.26	0.78	-0.66	0.68	0.34	0.74	0.78	0.88	0.79		0.03	0.14	0.67	0.67	0.49
Deferred Long Term Liab	-0.09	-0.12	0.47	-0.47	0.11	-0.08	0.25	-0.08	-0.3	-0.11	-0.6	-0.31	-0.14	0.2	-0.07	0.03		-0.63	-0.23	-0.2	-0.16
Short Long Term Debt	0.19	0.15	-0.75	0.47	-0.17	0.09	0.21	0.18	0.45	0.05	0.96	0.45	0.27	0.05	0.11	0.14	-0.63		0.22	0.2	0.08
Net Invested Capital	0.94	0.94	0.36	-0.51	-0.76	0.68	-0.24	0.94	-0.38	0.77	0.37	0.66	0.74	0.58	0.84	0.67	-0.23	0.22		1.0	0.77
Net Working Capital	0.94	0.94	0.37	-0.53	-0.75	0.67	-0.23	0.94	-0.4	0.77	0.35	0.66	0.74	0.59	0.85	0.67	-0.2	0.2	1.0		0.76
Capital Stock	0.7	0.68	0.31	-0.38	-0.9	0.88	-0.07	0.69	-0.2	0.83	0.2	0.45	0.43	0.36	0.42	0.49	-0.16	0.08	0.77	0.76

Click cells to compare fundamentals

About Kalvista Pharmaceuticals Financial Statements

Kalvista Pharmaceuticals investors use historical fundamental indicators, such as Kalvista Pharmaceuticals' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kalvista Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	5.62	(37.75)
Tangible Book Value Per Share	5.62	(37.75)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC